12-Month peak alpha frequency is a correlate but not a longitudinal predictor of non-verbal cognitive abilities in infants at low and high risk for autism spectrum disorder.

Autism spectrum disorder Cognitive development EEG Infant siblings Peak alpha frequency

Journal

Developmental cognitive neuroscience
ISSN: 1878-9307
Titre abrégé: Dev Cogn Neurosci
Pays: Netherlands
ID NLM: 101541838

Informations de publication

Date de publication:
04 2021
Historique:
received: 22 06 2020
revised: 10 12 2020
accepted: 01 03 2021
pubmed: 14 3 2021
medline: 13 10 2021
entrez: 13 3 2021
Statut: ppublish

Résumé

Although studies of PAF in individuals with autism spectrum disorder (ASD) report group differences and associations with non-verbal cognitive ability, it is not known how PAF relates to familial risk for ASD, and whether similar associations with cognition in are present in infancy. Using a large multi-site prospective longitudinal dataset of infants with low and high familial risk for ASD, metrics of PAF at 12 months were extracted and growth curves estimated for cognitive development between 12-36 months. Analyses tested whether PAF 1) differs between low and high risk infants, 2) is associated with concurrent non-verbal/verbal cognitive ability and 3) predicts developmental change in non-verbal/verbal ability. Moderation of associations between PAF and cognitive ability by familial risk status was also tested. No differences in 12-month PAF were found between low and high risk infants. PAF was associated with concurrent non-verbal cognitive ability, but did not predict change in non-verbal cognitive over development. No associations were found between PAF and verbal ability, along with no evidence of moderation. PAF is not related to familial risk for ASD, and is a neural marker of concurrent non-verbal cognitive ability, but not verbal ability, in young infants at low and high risk for ASD.

Identifiants

pubmed: 33714056
pii: S1878-9293(21)00029-3
doi: 10.1016/j.dcn.2021.100938
pmc: PMC7966984
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100938

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD055782
Pays : United States
Organisme : Wellcome Trust
ID : 213608/Z/18/Z
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : P50 HD103524
Pays : United States
Organisme : NIMH NIH HHS
ID : U19 MH108206
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Virginia Carter Leno (V)

Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK. Electronic address: virginia.carter_leno@kcl.ac.uk.

Andrew Pickles (A)

Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Stefon van Noordt (S)

Montreal Neurological Institute, Azrieli Centre for Autism Research, McGill University, Montréal, Canada.

Scott Huberty (S)

Montreal Neurological Institute, Azrieli Centre for Autism Research, McGill University, Montréal, Canada.

James Desjardins (J)

Compute Ontario, Canada.

Sara Jane Webb (SJ)

Center on Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, USA.

Mayada Elsabbagh (M)

Montreal Neurological Institute, Azrieli Centre for Autism Research, McGill University, Montréal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH